Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study

An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans

(2018) Adil Mardinoglu et al.   Cell Metabolism

Discovery, characterization, and clinical development of the glucagon-like peptides

(2017) Daniel J. Drucker et al.   JOURNAL OF CLINICAL INVESTIGATION

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

(2016) Marja-Riitta Taskinen et al.   Current Atherosclerosis Reports

The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis

(2016) Jan Borén et al.   CURRENT OPINION IN LIPIDOLOGY

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial

(2016) Peter Gæde et al.   DIABETOLOGIA

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

(2016) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

(2016) Matthew J. Armstrong et al.   JOURNAL OF HEPATOLOGY

Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia

(2016) A. E. Junker et al.   JOURNAL OF INTERNAL MEDICINE

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal ObesitySignificance

(2015) Jan Borén et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

New insights into the pathophysiology of dyslipidemia in type 2 diabetes

(2015) Marja-Riitta Taskinen et al.   ATHEROSCLEROSIS

Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors

(2015) Jixin Zhong et al.   Clinical Lipidology

Postprandial hypertriglyceridemia as a coronary risk factor

(2014) Jan Borén et al.   CLINICA CHIMICA ACTA

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

Hepatic lipogenesis and a marker of hepatic lipid oxidation, predict postprandial responses of triglyceride-rich lipoproteins

(2014) Niina Matikainen et al.   Obesity

GLP-1 Responses Are Heritable and Blunted in Acquired Obesity With High Liver Fat and Insulin Resistance

(2013) Niina Matikainen et al.   DIABETES CARE

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial

(2013) K. Hermansen et al.   DIABETES OBESITY & METABOLISM

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment

(2013) Anette Varbo et al.   PHARMACOLOGY & THERAPEUTICS

Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity

(2012) Martin Adiels et al.   ATHEROSCLEROSIS

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

(2012) M. Nauck et al.   DIABETES OBESITY & METABOLISM

The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes

(2012) N. Matikainen et al.   DIABETIC MEDICINE

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study

(2012) B. Eliasson et al.   DIABETOLOGIA

Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction

(2012) Anders Berg Jørgensen et al.   EUROPEAN HEART JOURNAL

Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects

(2011) Marja-Riitta Taskinen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

(2011) Gianluca Svegliati-Baroni et al.   LIVER INTERNATIONAL

Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series

(2010) Patrick R Kenny et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia

(2010) Sandrine Caron et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

(2010) Eric A. Schwartz et al.   ATHEROSCLEROSIS

One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress

(2010) Mathijs C. Bunck et al.   ATHEROSCLEROSIS

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase

(2010) Shani Ben-Shlomo et al.   JOURNAL OF HEPATOLOGY

ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan

(2009) A. Hiukka et al.   DIABETES

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

(2009) J. Jendle et al.   DIABETES OBESITY & METABOLISM

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE